MPLT

16.77

4.53% -0.795

Handel nachbörslich: 16.80 0.03 +0.18%

Maplight Therapeutics Inc (MPLT)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$17.57

Offen:

$17.4

24-Stunden-Volumen:

240.56K

Relative Volume:

1.10

Marktkapitalisierung:

$760.91M

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

-6.89%

1M Leistung:

+30.10%

6M Leistung:

+0.00%

1J Leistung:

+0.00%

1-Tages-Spanne:

$15.58

$17.78

1-Wochen-Bereich:

$15.58

$18.33

52-Wochen-Spanne:

$12.24

$21.55

Maplight Therapeutics Inc Stock (MPLT) Company Profile

Firmenname

Maplight Therapeutics Inc

Sektor

Healthcare (1131)

Branche

Biotechnology (631)

Telefon

Adresse

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-12-03

Neueste SEC-Einreichungen

MPLT's Discussions on Twitter

Vergleichen Sie MPLT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MPLT Maplight Therapeutics Inc	16.77	796.98M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	452.13	115.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.31	81.12B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.17	52.54B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	839.99	51.78B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	177.12	37.12B	447.02M	-1.18B	-906.14M	-6.1812

Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-21	Eingeleitet	Jefferies	Buy
2025-11-21	Eingeleitet	Leerink Partners	Outperform
2025-11-21	Eingeleitet	Morgan Stanley	Overweight
2025-11-21	Eingeleitet	Stifel	Buy

Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten

Dec 30, 2025

MapLight’s phase 2 Alzheimer’s psychosis trial marks a key milestone for MPLT investors - MSN

Dec 30, 2025

Dec 26, 2025

What is the current Price Target and Forecast for MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research

Dec 26, 2025

Dec 23, 2025

MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors - TipRanks

Dec 23, 2025

Dec 22, 2025

MapLight Therapeutics Earnings Notes - Trefis

Dec 22, 2025

MapLight Therapeutics advances CNS drug pipeline - MSN

Dec 22, 2025

MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors - TipRanks

Dec 22, 2025

Dec 21, 2025

MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P TMI Index - marketscreener.com

Dec 21, 2025

Dec 20, 2025

Aktis Oncology files for US IPO as biotech listings rebound - whbl.com

Dec 20, 2025

Dec 18, 2025

MapLight2025 Funding Rounds & List of Investors - Tracxn

Dec 18, 2025

MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to Russell 2000 Growth Index - marketscreener.com

Dec 18, 2025

Dec 17, 2025

SandboxAQ and MapLight form $200 million CNS drug discovery alliance By Investing.com - Investing.com Nigeria

Dec 16, 2025

SandboxAQ and MapLight form $200 million CNS drug discovery alliance - Investing.com

Dec 16, 2025

MapLight links up with SandboxAQ to pursue AI-discovered CNS treatments - Axios

Dec 16, 2025

SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies - The Manila Times

Dec 16, 2025

Sandboxaq And Maplight Therapeutics Announce Collaboration To Discover And Develop Novel CNS Therapies - TradingView — Track All Markets

Dec 16, 2025

Dec 12, 2025

MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN

Dec 12, 2025

Dec 08, 2025

Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN

Dec 08, 2025

Dec 07, 2025

MapLight Therapeutics completes IPO and raises $296.5M - MSN

Dec 07, 2025

Dec 06, 2025

Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (MPLT) and Halozyme (HALO) - The Globe and Mail

Dec 06, 2025

Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2025 - MarketBeat

Dec 06, 2025

Dec 05, 2025

symbol__ Stock Quote Price and Forecast - CNN

Dec 05, 2025

Adversity is less terrifying than hope: MapLight Therapeutics Inc (MPLT) - setenews.com

Dec 05, 2025

Dec 04, 2025

MapLight Therapeutics Advances CNS Drug Pipeline - TipRanks

Dec 04, 2025

Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech

Dec 04, 2025

Maplight Therapeutics (MPLT) Earnings Date and Reports 2026 - MarketBeat

Dec 04, 2025

Maplight Therapeutics reports third quarter financial results - marketscreener.com

Dec 04, 2025

MapLight Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com

Dec 04, 2025

MapLight Therapeutics Completes IPO and Raises $296.5M - TipRanks

Dec 04, 2025

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress - The Manila Times

Dec 04, 2025

MapLight Therapeutics, Inc. SEC 10-Q Report - TradingView

Dec 04, 2025

MPLT: Clinical pipeline advances and robust IPO funding position operations through 2027 - TradingView — Track All Markets

Dec 04, 2025

Dec 03, 2025

Positive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts - TipRanks

Dec 03, 2025

MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug By Investing.com - Investing.com South Africa

Dec 03, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Dec 03, 2025

MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug - Investing.com Canada

Dec 03, 2025

Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus

Dec 03, 2025

Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday - Benzinga

Dec 03, 2025

Dec 02, 2025

SETIA VISHWAS Insider Trades - Nasdaq

Dec 02, 2025

Dec 01, 2025

MapLight Therapeutics (MPLT) Stock Analysis Report | Financials & Insights - Benzinga

Dec 01, 2025

Nov 28, 2025

MPLT Interactive Stock Chart | MapLight Therapeutics, Inc. Stock - Yahoo! Finance Canada

Nov 28, 2025

Nov 27, 2025